From: Damien R. Sullivan (phoenix@ugcs.caltech.edu)
Date: Mon Aug 10 1998 - 19:45:04 MDT
The embargoed high biotech island of libertarian SF turns out to be
Cuba. I find this quite amusing.
http://www.latimes.com/HOME/NEWS/FRONT/t000072938.html
Summary: SmithKline has partnered with Cuba to market their group B
meningococcal vaccine, and has applied for an embargo waiver in the US.
(The vaccine fights group B meningitis.) One team is in the first phase
of human clinical trials of an AIDS vaccine they hope will be ready for
commercial use in 2 years. Another group is "perfecting" a cholera
vaccine. Biotech is now Cuba's 4th largest export earner. US market
analysts confirm Cuba has state-of-the-art research and production
capability.
<quote>
In recent years, the government has invested hundreds of millions of
dollars in biotech facilities and research. That has created something of a
technology gap here: scientists using advanced genetic techniques to clone
fish in a land where the U.S. embargo has made antibiotics scarce on hospital
shelves and smoke-belching, '50s-vintage Chevys and Buicks commonplace on the
streets.
Dr. Mario Pablo Estrada, who heads the fish-transgenesis project,
explains the phenomenon with simple mathematics: "With $7 million, we couldn't
even begin to produce our own basic medicines," which he said are far more
costly to mass produce than highly specialized "niche" products such as
vaccines. "But with a $7-million investment here at the genetic research
center, we can make $30 million in sales, and we can use that to buy a lot of
basic medicines."
</quote>
-xx- Damien R. Sullivan X-)
This archive was generated by hypermail 2.1.5 : Fri Nov 01 2002 - 14:49:26 MST